These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 27520379)
1. Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses. Chow EC; Talattof A; Tsakalozou E; Fan J; Zhao L; Zhang X AAPS J; 2016 Nov; 18(6):1500-1511. PubMed ID: 27520379 [TBL] [Abstract][Full Text] [Related]
3. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs. Flanagan T Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247 [TBL] [Abstract][Full Text] [Related]
4. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. Metry M; Shu Y; Abrahamsson B; Cristofoletti R; Dressman JB; Groot DW; Parr A; Langguth P; Shah VP; Tajiri T; Mehta MU; Polli JE J Pharm Sci; 2021 Apr; 110(4):1513-1526. PubMed ID: 33450218 [TBL] [Abstract][Full Text] [Related]
5. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs. Melillo N; Aarons L; Magni P; Darwich AS J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544 [TBL] [Abstract][Full Text] [Related]
6. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers. Parr A; Hidalgo IJ; Bode C; Brown W; Yazdanian M; Gonzalez MA; Sagawa K; Miller K; Jiang W; Stippler ES Pharm Res; 2016 Jan; 33(1):167-76. PubMed ID: 26286187 [TBL] [Abstract][Full Text] [Related]
9. Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs. Ren P; Chan T; Yang WC; Frost M; Wang Y; Luke M; Kim MJ; Lionberger R; Zhang Y Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765334 [TBL] [Abstract][Full Text] [Related]
10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
11. The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model. Yamane M; Matsui K; Sugihara M; Tokunaga Y J Pharm Sci; 2021 Jan; 110(1):467-477. PubMed ID: 32470348 [TBL] [Abstract][Full Text] [Related]
12. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273 [TBL] [Abstract][Full Text] [Related]
13. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626 [TBL] [Abstract][Full Text] [Related]
14. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140 [TBL] [Abstract][Full Text] [Related]
15. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204 [TBL] [Abstract][Full Text] [Related]
17. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Markovic M; Zur M; Ragatsky I; Cvijić S; Dahan A Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276565 [TBL] [Abstract][Full Text] [Related]